1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On April 30, 2026, Intel issued $6.5 billion of senior notes in five tranches maturing between 2031 and 2066, with net proceeds of approximately $6.47 billion before expenses. The debt was sold under an underwriting agreement dated April 27, 2026, and adds to Intel's long-term borrowings, which shareholders will need to service over time.
Five tranches: $1.0 billion of 4.650% notes due 2031, $1.0 billion of 5.000% notes due 2033, $2.25 billion of 5.300% notes due 2036, $1.75 billion of 6.125% notes due 2056, and $500 million of 6.200% notes due 2066
Approximate net proceeds of $6.47 billion, before expenses and after underwriting discounts
Offering registered under a Form S-3 filed January 23, 2026; notes issued under a supplemental indenture with Computershare Trust Company as trustee
Underwriter representatives include Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BofA Securities, Inc., and Deutsche Bank Securities Inc.
On April 30, 2026, AT&T closed the sale of five series of Global Notes with total principal of $6.0 billion, maturing from 2033 to 2066 and carrying coupons from 4.750% to 6.300%. The notes were issued under an underwriting agreement dated April 23, 2026, and registered under an existing Form S-3 shelf. The filing adds $6.0 billion of debt obligations for shareholders to consider, but it reports no change to earnings or guidance.
Five tranches: $750 million 4.750% notes due 2033, $1.75 billion 5.250% due 2036, $500 million 5.850% due 2046, $2.0 billion 6.200% due 2056, and $1.0 billion 6.300% due 2066
Underwriting agreement dated April 23, 2026, with BBVA Securities, J.P. Morgan, Mizuho, Santander, SG Americas and SMBC Nikko as representatives
Notes issued under a 2013 indenture with The Bank of New York Mellon Trust Company, N.A., as trustee
Sonoma Pharmaceuticals sold shares, pre-funded warrants and warrants in a public offering priced at $1.35 per unit, with the offering closing on April 27 and 28, 2026, including full exercise of the underwriter's over-allotment option. The company expects net proceeds of about $3.5 million, and the filing also discloses warrants that could bring in additional cash, which adds potential share dilution for existing shareholders.
Priced April 24, 2026 at $1.35 per unit; closed April 27 and 28, 2026, with full exercise of the 45-day over-allotment option.
Issued 1,650,716 common shares, 1,312,247 pre-funded warrants and 3,407,404 warrants exercisable at $1.35 per share, expiring on the fifth anniversary of issuance.
Net proceeds expected to be about $3.5 million after a 7.5% underwriting fee, a 1% expense allowance and other offering expenses.
Underwriter warrant for up to 5% of securities sold; the company and its officers and directors agreed to a 90-day restriction on sales, subject to limited exceptions.
Phibro Animal Health entered into Amendment No. 1 to its credit agreement with Coöperatieve Rabobank U.A., New York Branch, on April 28, 2026. The amendment increases the revolving credit commitment by $125 million, from $310 million to $435 million, giving the company more borrowing capacity under its existing facility.
Revolving credit commitment rose by $125 million, from $310 million to $435 million
Amendment No. 1 is dated April 28, 2026, and amends the Original Credit Agreement dated July 3, 2024
Rabobank acts as administrative agent, collateral agent and L/C issuer
HCA Inc., a wholly owned subsidiary of HCA Healthcare, completed a public offering of $3 billion of senior unsecured notes on April 30, 2026. The notes are guaranteed by HCA Healthcare and are registered under a shelf registration statement, so the filing adds $3 billion of debt for the company group.
Three tranches: $1 billion of 4.700% notes due May 15, 2031; $750 million of 5.000% notes due May 15, 2033; and $1.25 billion of 5.300% notes due May 15, 2036
Interest is payable semi-annually on May 15 and November 15, starting November 15, 2026
Notes are fully and unconditionally guaranteed by HCA Healthcare, Inc. on a senior unsecured basis
Underwriting agreement dated April 27, 2026, with Citigroup, Barclays, BofA Securities and J.P. Morgan as representatives of the underwriters
Lumen Technologies entered into supplemental indentures and a parent guarantee agreement on April 30, 2026, providing unconditional senior unsecured guarantees of Level 3's first lien notes and its credit facilities. As a result, Level 3 Parent will stop filing reports with the SEC, and Level 3 will meet its reporting duties by furnishing Lumen's filings, which will include summary financial information of Level 3 Parent. The filing describes the changes as administrative simplification and reports no financial results.
Lumen guarantees Level 3's 6.875% first lien notes due 2033 and 7.000% first lien notes due 2034, subject to release terms in the indentures
Lumen also guarantees Level 3's obligations under its Credit Agreement dated March 22, 2024, with Wilmington Trust as administrative agent
Level 3 Parent, LLC will no longer file reports with the Securities and Exchange Commission
Camden Property Trust entered into replacement at-the-market sales agreements on April 28, 2026, to renew a program that expires May 12, 2026. The agreements allow the company to sell common shares with an aggregate offering price of up to $500 million through five banks and their affiliates. The filing says proceeds may be used for general corporate purposes, including reducing borrowings under its $1.2 billion revolving credit facility.
Program size: common shares with an aggregate offering price of up to $500,000,000
Existing program expires pursuant to its terms on May 12, 2026; agreements dated April 28, 2026
Managers include Deutsche Bank Securities, BMO Capital Markets, Regions Securities, Scotia Capital and Truist Securities
Compensation to each manager will not exceed 1.5% of gross sales price of shares sold through it
On April 28, 2026, Syntec Optics agreed to sell 2,857,142 shares of common stock at $7.00 per share in an underwritten offering led by H.C. Wainwright & Co., with expected gross proceeds of about $20 million before underwriting discounts and expenses. The offering is expected to close on April 30, 2026, and the company plans to use the net proceeds for acquisitions or investments, working capital, capital expenditures and possibly repaying debt, including a subordinated term note with its majority stockholder. The new shares increase the number of shares outstanding, and the company has agreed to restrictions on further stock issuances for 90 days after closing.
2,857,142 shares priced at $7.00 per share; underwriters purchased them at $6.58 per share
Expected gross proceeds of about $20 million; underwriter has a 30-day option for up to 428,571 additional shares
Closing expected April 30, 2026; proceeds may repay part of a $1,268,732.49 subordinated term note with the majority stockholder
Company agreed not to issue additional common stock for 90 days after closing; underwriter discount is 6.0% of gross proceeds
Walmart agreed to sell $4.2 billion of senior unsecured notes in five new series, maturing in 2029, 2031, 2033 and 2036, through underwriters including Citigroup and J.P. Morgan. The company expects the sale to close on April 30, 2026, with net proceeds of about $4.23 billion before transaction expenses, which adds to its long-term debt.
Total principal of $4,245,848,500 across floating rate notes due 2029, 4.000% notes due 2029, 4.150% notes due 2031, 4.450% notes due 2033 and 4.750% notes due 2036
Net proceeds to the company of $4,230,348,500 after underwriting discounts, before transaction expenses
Pricing agreement dated April 27, 2026; closing expected April 30, 2026; sold under an existing S-3ASR shelf registration
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.